23 results
Thumbnail

D2.65 - Clinical relevance of sensitizations to pneumoallergens detected in southern Spain

Thumbnail

D2.66 - Deciphering The Molecular Profiles Between Asthma and Urticaria Using Transcriptomic Profiling

Thumbnail

D2.67 - Relation betwween IL-6 and asthma in children and adolescent

Thumbnail

D2.69 - Symptom Variability in Hypereosinophilic Syndrome: Observations From a Large Cohort Study

Thumbnail

D2.70 - The Impact of Comorbidity of respiratory and atopic diseases on Mental Health and Wellbeing: a Community Survey in the US and Eastern Europe

Thumbnail

D2.71 - Comprehensive approach to severe bronchial asthma: a case study and the role of biologic therapy

Thumbnail

D2.72 - Analysis of asthma prevalence and risk factors in infantile atopic dermatitis using data from the Korean national health insurance serice

Thumbnail

D2.73 - Activation-induced marker (AIM) assay to study allergic skin reactions: a case study on p-phenylenediamine

Thumbnail

D2.74 - Analytical Verification of House Dust Mite Allergen Assays on the IMMULITE 2000 XPi System*

Thumbnail

D2.75 - Allergy to insects in children

Thumbnail

D2.76 - When Eosinophilia Persists: Unmasking an Unexpected Diagnosis in a Dupilumab Treated Atopic Dermatitis Patient

Thumbnail

D2.77 - A Novel Neural Network for Quantifying Wheal and Erythema in Skin Prick Testing

Thumbnail

D2.78 - Hypersensitivity Reactions to Biologics in Patients with Th1- and Th17-Driven Immune-Mediated Diseases: A Series of Three Cases

Thumbnail

D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab

Thumbnail

D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab

Thumbnail

D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis

Thumbnail

D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic

Thumbnail

D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates

Thumbnail

D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab

Thumbnail

D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results